Product Details
| Product Name: Mirabeiron Nitroso Impurity 57 | Min. Order: 10mg |
| Purity: 99%+ HPLC | Supply Ability: 1000 |
| Release date: 2025/08/01 | |
| Molecular formula: C21H23N5O2S |
Mirabeiron Nitroso Impurity 57;C21H23N5O2S

Product Information
Product Number: M005057
English Name: Mirabeiron Nitroso Impurity 57
English Alias: 2-(2-aminothiazol-4-yl)-N-(4-(2-(nitroso(phenethyl)amino)ethyl)phenyl)acetamide
CAS Number: None
Molecular Formula: C₂₁H₂₃N₅O₂S
Molecular Weight: 409.50
Advantages
Well-defined with distinct functional groups: Contains 2-aminothiazole ring, N-phenylacetamide, and 4-(2-(nitroso(phenethyl)amino)ethyl) side chain. Unlike mirabegron (β₃-adrenergic agonist), its nitrosoamide (-N-NO) polarity, thiazole aromaticity, and phenethyl hydrophobicity create significant differences, enabling precise differentiation via HPLC/ion-pair chromatography as a specific marker;
High stability and traceability: Rigid thiazole/benzene structures and stability of amide/nitrosoamide ensure stability under dark, low-temperature conditions. As a derivative from amine nitrosation during storage/synthesis, it directly reflects amino stability and nitrite exposure, improving impurity tracing accuracy;
High detection sensitivity: Polycyclic conjugation shows strong UV absorption (240-280nm), combined with m/z 410 [M+H]⁺ enabling ppb-level analysis via LC-MS, compatible with urinary drug nitroso impurity systems.
Applications
Pharmaceutical quality control: Used as an impurity reference standard to quantify Mirabeiron Nitroso Impurity 57 in APIs, ensuring compliance with genotoxic impurity limits in pharmaceutical standards;
Stability studies: Monitoring impurity levels under varying conditions (pH, light) to assess degradation trends and support shelf-life assurance;
Synthesis assessment: Evaluating purity of amino-containing intermediates in mirabegron synthesis to reduce nitrosation risk at the source.
Background Description
Research Status
Analytical method validation: Developing UPLC-MS/MS methods with C18 columns for separation, achieving 0.01 ppb detection limits;
Nitrosation mechanism: Studying impurity formation kinetics under varying nitrite concentration and pH to clarify phenethylamino-to-nitrosoamide conversion pathways;
Control strategies: Exploring nitrosation inhibitors (e.g., ascorbic acid) to keep impurity levels below safety limits (<0.001%);
Toxicity evaluation: Conducting in vitro genotoxicity tests (e.g., Ames test) to assess potential hazards and support limit setting.
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/5mg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2025-01-16 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2025-03-31 | |
| $0.00/10mg |
VIP1Y
|
Guangzhou Weiaokang Pharmaceutical Technology Co., Ltd
|
2025-08-01 |

China